Global Analysis of Pulmonary Edema Market Size, Growth and Forecast
Report ID : 1356459 | Published : May 2025 | Study Period : 2023-2033 | Format : PDF + Excel
The market size of the Pulmonary Edema Market is categorized based on Type (Cardiogenic Pulmonary Edema, Non-cardiogenic Pulmonary Edema) and Treatment (Medications, Oxygen Therapy, Mechanical Ventilation, Others) and End User (Hospitals, Clinics, Home Healthcare, Others) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).
With a valuation of $2.5 billion in 2023, the Pulmonary Edema Market is expected to reach $4.5 billion by 2033, growing at a CAGR of 6.3% from 2024 onwards. The report encompasses various segments and analyzes the trends and factors significantly impacting the market.
The Pulmonary Edema Market is expanding at a robust pace because of an increase in the respiratory ailments and the growth of the Pulmonary Edema Market Medical Technology sector. Medical technology pulmonary edema, or lung swelling which results in fluid build-up in the lungs requiring urgent medical attention, is potentially life-threatening requiring swift resolution and treatment. With the current healthcare policies worldwide geared towards improving patient care, there is a growing need for new treatments, therapies, and diagnostic instruments which is favorable for the industry players.
The research conducted suggests that the Pulmonary Edema Market is affected by the growing elderly populations, rising levels of pollution, and the increasing prevalence of chronic diseases like heart ailments and hypertension. Having these factors reinforces the need to effectively manage and treat the illnesses which, in turn, helps propel the market. Additionally, there is active PERD seeking to improve treatment methods and patient ELM accessibility which is bound to expand the growth of the market and increase stake-holder interest.
While examining the details of the Pulmonary Edema Market, it becomes damningly clear that gaining insight into the competitive market, legal restrictions, and current changes is significant to be able to value the new opportunities present. Bringing forth important participants and their strategic business initiatives will help forecast the market to assist economically crucial businesses within the healthcare sectors.
| ATTRIBUTES | DETAILS |
| STUDY PERIOD | 2023-2033 |
| BASE YEAR | 2023 |
| FORECAST PERIOD | 2024-2033 |
| HISTORICAL PERIOD | 2023-2024 |
| UNIT | VALUE (USD BILLION) |
| KEY COMPANIES PROFILED | Pfizer Inc., Roche Holding AG, Novartis AG, Boehringer Ingelheim GmbH, AstraZeneca PLC, Merck & Co. Inc., GlaxoSmithKline PLC, Johnson & Johnson, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company |
| SEGMENTS COVERED |
By Type - Cardiogenic Pulmonary Edema, Non-cardiogenic Pulmonary Edema
By Treatment - Medications, Oxygen Therapy, Mechanical Ventilation, Others
By End User - Hospitals, Clinics, Home Healthcare, Others
By Geography - North America, Europe, APAC, Middle East Asia & Rest of World. |
Pulmonary Edema Market Dynamics
The Pulmonary Edema Market is undergoing significant changes due to various dynamic factors. This section delves into the key drivers, restraints, opportunities, and challenges that are shaping the market landscape.
Market Drivers
- Technological Advancements
- Increasing Consumer Demand
- Regulatory Support
- Globalization
Market Restraints
- High Operational Costs
- Regulatory Challenges
- Market Saturation
Market Opportunities
- Emerging Markets
- Product Innovation
- Strategic Partnerships
Market Challenges
- Technological Disruptions
- Supply Chain Issues
- Changing Consumer Preferences
Pulmonary Edema Market Segmentations
Market Breakup by Type
- Overview
- Cardiogenic Pulmonary Edema
- Non-cardiogenic Pulmonary Edema
Market Breakup by Treatment
- Overview
- Medications
- Oxygen Therapy
- Mechanical Ventilation
- Others
Market Breakup by End User
- Overview
- Hospitals
- Clinics
- Home Healthcare
- Others
Market Breakup by Region
North America
- United States of America
- Canada
- Mexico
Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Key Players in the Pulmonary Edema Market
This report provides an in-depth analysis of both established and rising industry participants. It provides broad lists of important companies organized by the types of products they offer and other market-related factors. In addition to characterizing these companies, the report contains the year each player entered the market, which is useful for research analysis by the study's analysts.
- Pfizer Inc.
- Roche Holding AG
- Novartis AG
- Boehringer Ingelheim GmbH
- AstraZeneca PLC
- Merck & Co. Inc.
- GlaxoSmithKline PLC
- Johnson & Johnson
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Bristol-Myers Squibb Company
Customization Options
Verified Industry Insights offers one of the following report customization options to our respectable clients :
Company Profiling
● Detailed profiling of additional market players (up to three players)
● SWOT analysis of key players (up to three players)
Competitive Benchmarking
● Benchmarking of key players on the following parameters : Product portfolio, geographical reach, regional presence, and strategic alliances.
Custom Research
Verified Industry Insights offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected] or call us at +1 743 222 5439
© 2024 Verified Industry Insights. All Rights Reserved